RU2008143703A - ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА - Google Patents
ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА Download PDFInfo
- Publication number
- RU2008143703A RU2008143703A RU2008143703/15A RU2008143703A RU2008143703A RU 2008143703 A RU2008143703 A RU 2008143703A RU 2008143703/15 A RU2008143703/15 A RU 2008143703/15A RU 2008143703 A RU2008143703 A RU 2008143703A RU 2008143703 A RU2008143703 A RU 2008143703A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- leukemia
- formula
- src
- activity
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title claims abstract 13
- 102000001332 SRC Human genes 0.000 title claims abstract 4
- 108060006706 SRC Proteins 0.000 title claims abstract 4
- 239000003112 inhibitor Substances 0.000 title claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 230000000694 effects Effects 0.000 claims abstract 10
- 102000029330 CSK Tyrosine-Protein Kinase Human genes 0.000 claims abstract 7
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000009097 single-agent therapy Methods 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- -1 4-methylpiperazinomethyl Chemical group 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 229940122924 Src inhibitor Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical group C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79043706P | 2006-04-07 | 2006-04-07 | |
| US60/790,437 | 2006-04-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012147511/15A Division RU2012147511A (ru) | 2006-04-07 | 2012-11-08 | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008143703A true RU2008143703A (ru) | 2010-05-20 |
Family
ID=38512209
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008143703/15A RU2008143703A (ru) | 2006-04-07 | 2007-04-05 | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА |
| RU2012147511/15A RU2012147511A (ru) | 2006-04-07 | 2012-11-08 | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012147511/15A RU2012147511A (ru) | 2006-04-07 | 2012-11-08 | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100152198A1 (enExample) |
| EP (1) | EP2010182A2 (enExample) |
| JP (2) | JP2009532438A (enExample) |
| KR (2) | KR20090031855A (enExample) |
| CN (1) | CN101415426A (enExample) |
| AU (1) | AU2007235976A1 (enExample) |
| BR (1) | BRPI0710675A2 (enExample) |
| CA (1) | CA2644841C (enExample) |
| MX (1) | MX2008012903A (enExample) |
| RU (2) | RU2008143703A (enExample) |
| WO (1) | WO2007116025A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1848414T3 (da) | 2005-02-03 | 2011-07-25 | Gen Hospital Corp | Fremgangsmåde til behandling af gefitinib-resistent cancer |
| AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| SI2310011T1 (sl) | 2008-06-17 | 2013-10-30 | Wyeth Llc | Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin |
| BRPI0916694B1 (pt) * | 2008-08-04 | 2021-06-08 | Wyeth Llc | uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos |
| EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
| WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| CN103113355B (zh) * | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN116178358B (zh) * | 2022-11-04 | 2024-04-19 | 济南大学 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH690773A5 (de) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| WO2002000024A1 (en) * | 2000-06-30 | 2002-01-03 | The Regents Of The University Of California | New strategy for leukemia therapy |
| WO2002062334A2 (en) * | 2001-02-05 | 2002-08-15 | Pezzuto John M | Cancer chemopreventative compounds and compositions and methods of treating cancers |
| AU2002345670A1 (en) * | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
| EP1418917A1 (en) * | 2001-08-10 | 2004-05-19 | Novartis AG | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| EP1473043A1 (en) * | 2003-04-29 | 2004-11-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis |
| AU2003291245A1 (en) * | 2003-11-06 | 2004-06-06 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| US20060069101A1 (en) * | 2004-09-27 | 2006-03-30 | Kim Kyoung S | Prodrugs of protein tyrosine kinase inhibitors |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. |
-
2007
- 2007-04-05 MX MX2008012903A patent/MX2008012903A/es active IP Right Grant
- 2007-04-05 JP JP2009503591A patent/JP2009532438A/ja active Pending
- 2007-04-05 BR BRPI0710675-0A patent/BRPI0710675A2/pt not_active IP Right Cessation
- 2007-04-05 US US12/295,832 patent/US20100152198A1/en not_active Abandoned
- 2007-04-05 WO PCT/EP2007/053399 patent/WO2007116025A2/en not_active Ceased
- 2007-04-05 KR KR1020087027245A patent/KR20090031855A/ko not_active Ceased
- 2007-04-05 AU AU2007235976A patent/AU2007235976A1/en not_active Abandoned
- 2007-04-05 CN CNA2007800120868A patent/CN101415426A/zh active Pending
- 2007-04-05 KR KR1020117016784A patent/KR101292508B1/ko not_active Expired - Fee Related
- 2007-04-05 EP EP07727867A patent/EP2010182A2/en not_active Withdrawn
- 2007-04-05 RU RU2008143703/15A patent/RU2008143703A/ru unknown
- 2007-04-05 CA CA2644841A patent/CA2644841C/en not_active Expired - Fee Related
-
2012
- 2012-09-24 US US13/625,299 patent/US20130040972A1/en not_active Abandoned
- 2012-11-08 RU RU2012147511/15A patent/RU2012147511A/ru not_active Application Discontinuation
-
2013
- 2013-01-31 JP JP2013016980A patent/JP2013136596A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0710675A2 (pt) | 2011-08-23 |
| KR20110097966A (ko) | 2011-08-31 |
| CA2644841A1 (en) | 2007-10-18 |
| MX2008012903A (es) | 2008-10-13 |
| KR20090031855A (ko) | 2009-03-30 |
| KR101292508B1 (ko) | 2013-08-01 |
| RU2012147511A (ru) | 2014-05-20 |
| WO2007116025A3 (en) | 2007-12-13 |
| WO2007116025A2 (en) | 2007-10-18 |
| AU2007235976A1 (en) | 2007-10-18 |
| US20100152198A1 (en) | 2010-06-17 |
| US20130040972A1 (en) | 2013-02-14 |
| CN101415426A (zh) | 2009-04-22 |
| JP2009532438A (ja) | 2009-09-10 |
| JP2013136596A (ja) | 2013-07-11 |
| EP2010182A2 (en) | 2009-01-07 |
| CA2644841C (en) | 2013-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА | |
| JP2009532438A5 (enExample) | ||
| JP2005502643A5 (enExample) | ||
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| RU2005102098A (ru) | Амидное производное | |
| KR100848197B1 (ko) | 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 | |
| JP2005527523A (ja) | ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド | |
| AU2002308218A1 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
| TR201806682T4 (tr) | Farmasötik kombinasyonlar. | |
| RU2006125741A (ru) | Комбинация (а) n-{5-[4-(4-метилпиперазинометил)бензоиламило]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамина и (б) по меньшей мере одного ингибитора гипузинации и ее применение | |
| RU2008143704A (ru) | КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle | |
| US20150209362A1 (en) | Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor | |
| RU2018108804A (ru) | Фармацевтические комбинации и их применение | |
| JP2007514699A5 (enExample) | ||
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| RU2007103703A (ru) | Комбинация, включающая ингибитор бррм (белка резистентности рака молочной железы) и 4-(4-метилпиперазин-1-илметил)-n-(4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил)-бензамид | |
| JP2005507410A5 (enExample) | ||
| RU2008105832A (ru) | Органические соединения | |
| RU2008105828A (ru) | Комбинация пиримидиламинобензамида и ингибитора киназ mtor | |
| RU2007135284A (ru) | Фармацевтические комбинации ингибиторов киназ bcr-abl и raf | |
| WO2014148438A1 (ja) | ４－（１，１，１，３，３，３－ヘキサフルオロ－２－ヒドロキシプロパン－２－イル）ベンゼン誘導体を含有するｃ型肝炎治療剤 | |
| RU2020126673A (ru) | Комбинированные терапии для лечения гепатоцеллюлярной карциномы |